Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2018

Revenue from Contract with Customer [Abstract]

Net product sales consist of the following:



	Three Months Ended June 30,				Six Months Ended June 30,
Net Product Sales in the United States	2018		2017		2018		2017
EYLEA^®	$	991,998	$	919,466	$	1,976,047	$	1,773,853
ARCALYST^®	4,384		4,667		8,244		8,525
	$	996,382	$	924,133	$	1,984,291	$	1,782,378

The collaboration revenue we earned from Sanofi is detailed below:



	Three Months Ended June 30,						Six Months Ended June 30,
Sanofi Collaboration Revenue	2018			2017			2018			2017
Antibody:
Reimbursement of Regeneron research and development expenses	$	64,482		$	137,272		$	124,876		$	292,517
Reimbursement of Regeneron commercialization-related expenses	103,666			87,104			189,090			160,663
Regeneron's share of losses in connection with commercialization of antibodies	(68,797		)	(122,281		)	(143,671		)	(230,683		)
Other	31,654			31,204			48,984			42,490
Total Antibody	131,005			133,299			219,279			264,987
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	77,054			68,080			150,878			126,759
Reimbursement of Regeneron commercialization-related expenses	2,061			749			3,271			749
Other	27,633			20,000			53,815			40,000
Total Immuno-oncology	106,748			88,829			207,964			167,508
	$	237,753		$	222,128		$	427,243		$	432,495

Revenue earned in connection with our Bayer EYLEA collaboration is detailed below:



	Three Months Ended June 30,				Six Months Ended June 30,
Bayer EYLEA Collaboration Revenue	2018		2017		2018		2017
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	246,302	$	190,883	$	478,370	$	365,759
Reimbursement of Regeneron EYLEA development expenses	3,678		2,329		7,135		4,780
Other	12,694		10,593		24,557		21,196
	$	262,674	$	203,805	$	510,062	$	391,735

Schedule of accounts receivable and deferred revenue information

The following table summarizes accounts receivable and deferred revenue information in connection with the Company's Antibody Collaboration with Sanofi:



	June 30,		December 31,
	2018		2017
Accounts receivable, net	$	160,954	$	121,001
Deferred revenue	$	170,906	$	117,682

Significant changes in deferred revenue balances are as follows:



	Six Months Ended June 30, 2018
Increase due to shipments of commercial supplies to Sanofi	$	108,359
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(55,135	)

The following tables summarize accounts receivable and deferred revenue information in connection with the Teva Collaboration Agreement:



	June 30,		December 31,
	2018		2017
Accounts receivable, net (recorded within Prepaid expenses and other current assets)	$	35,504	$	71,297
Deferred revenue	$	194,564	$	197,357

Significant changes in deferred revenue balances are as follows:



	Six Months Ended June 30, 2018
Increase as a result of cumulative-effect adjustment arising from the adoption of ASC 606	$	48,216
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(52,826	)

The following table summarizes accounts receivable and deferred revenue information in connection with the Company's IO Collaboration with Sanofi:



	June 30,		December 31,
	2018		2017
Accounts receivable, net	$	76,522	$	59,274
Deferred revenue	$	476,312	$	440,000

Significant changes in deferred revenue balances are as follows:



	Six Months Ended June 30, 2018
Increase as a result of cumulative-effect adjustment arising from the adoption of ASC 606	$	93,643
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(57,331	)

The following table summarizes accounts receivable and deferred revenue information in connection with the Company's EYLEA collaboration with Bayer:



	June 30,		December 31,
	2018		2017
Accounts receivable, net	$	261,646	$	241,153
Deferred revenue	$	73,750	$	68,734

Significant changes in deferred revenue balances are as follows:



	Six Months Ended June 30, 2018
Increase due to shipments of commercial supplies to Bayer	$	24,666
Revenue recognized that was included in deferred revenue at the beginning of the period	$	(19,650	)